BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 22, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/19 cls
Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) Deutsche Bank Robyn Karnauskas Price target Buy 23% 19.6
Jefferies Eun Yang Price target Buy
Karnauskas raised her target to $30 from $19 after FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-2 that efficacy and safety data for Aegerion' lomitapide support approval to treat homozygous familial hypercholesterolemia (hoFH) (see B10). She assumes a launch early next year and estimates lomitapide will generate peak worldwide sales of about $500M in adults and about $160M in pediatric patients. The small molecule microsomal triglyceride transfer protein (MTP) inhibitor has a Dec. 29 PDUFA date.
Yang raised her target to $22 from $20 on the panel vote. She expects Aegerion to launch lomitapide in the U.S. in early 2013 and in the EU in 2H13. Yang estimates peak lomitapide...

Read the full 933 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >